
There are three important considerations in the development of novel drug therapies: firstly, whether a suitable target can be accurately defined; secondly, does the target allow discrimination between normal cells and tumour cells; and thirdly, how easily could the tumour cells acquire resistance? This article will concentrate on two of the genetic alterations most commonly associated with multistep tumourigenesis, and discuss their potential as therapeutic targets with respect to the considerations above.

